Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 29, 2015 6:19 AM ET

Healthcare Equipment and Supplies

Company Overview of Medinol Ltd.

Company Overview

Medinol Ltd. engages in the research, development, manufacture, and marketing of cardiovascular intervention solutions. It offers bare metal stents and elastomer-based drug-eluting stents. The company was founded in 1992 and is based in Tel Aviv, Israel.

Building 8

35th Floor

Kiryat Atidim

POB 58165

Tel Aviv,  6158101


Founded in 1992


972 3 767 9000


972 3 648 2310

Key Executives for Medinol Ltd.

Founder, Chief Executive Officer and Director
Age: 68
Founder, Chairman and Chief Technology Officer
Age: 70
Vice President of Finance
Vice President of Human Resource and Infrastructure
Vice President of Innovative Technologies
Compensation as of Fiscal Year 2015.

Medinol Ltd. Key Developments

Medinol Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-18-2015 10:15 AM

Medinol Ltd. Presents at Life Sciences Israel(TM) 2015, Feb-18-2015 10:15 AM. Venue: Dan Panorama Hotel, Charles Clore Park, Tel Aviv 68012, Israel. Speakers: Hillegonda Groen, Vice President Marketing & Sales Europe.

ARIAD and Medinol Announce Initiation of Two Registration Trials of the Nirsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease

ARIAD Pharmaceuticals Inc. announced the initiation of two registration trials of Medinol's NIRsupreme(TM) Ridaforolimus-Eluting Coronary Stent System incorporating ARIAD's mTOR inhibitor, ridaforolimus. The two NIRsupreme clinical trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and Canada and will enroll approximately 2,200 patients with coronary artery disease. ARIAD licensed ridaforolimus to Medinol for use in drug-eluting stents in 2005. Drug-eluting stents (DES) are now implanted in over 500,000 patients yearly in the United States. The commencement of patient enrollment in Medinol's clinical trials, along with the submission of an investigational device exemption with the U.S. Food and Drug Administration, triggers milestone payments to ARIAD of $3.75 million, with the potential for additional regulatory, clinical and sales milestones, as well as royalties on product sales. The BIONICS trial aims to show that the NIRsupreme stent is comparable (non-inferior) to a comparator drug-eluting stent with the primary endpoint of coronary target lesion failure (a composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization) at 12 months. This trial is expected to enroll approximately 1,900 patients. The NIREUS trial aims to demonstrate angiographic non-inferiority of the NIRsupreme stent to a comparator stent and has a primary endpoint of late loss in lumen diameter within the stent determined by coronary angiography at six months. This trial is expected to enroll approximately 300 patients. ARIAD entered into a non-exclusive agreement with Medinol to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent reblockage of injured vessels following stent-assisted angioplasty. ARIAD is eligible to receive additional regulatory, clinical and commercial milestones of up to $34.75 million, if two products are developed, plus royalties on worldwide product sales. ARIAD is responsible for supplying ridaforolimus to Medinol, and Medinol is responsible for the development and commercialization of the medical devices delivering ridaforolimus. These rights are separate from those licensed to Merck for use of ridaforolimus in oncology.

Similar Private Companies By Industry

Company Name Region
Novel Erna Ltd. Middle East/Africa
MRI Microsystems Ltd. Middle East/Africa
Disc-O-Tech Medical Technologies Ltd. Middle East/Africa
Laminate Medical Technologies Ltd. Middle East/Africa
Flexicath Ltd. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Medinol Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at